This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
The two-week COP26 climate conference has now ended with leaders reaching a deal, but so far the deal is getting mixed reviews from climate experts across the globe. Chloe Demrovsky, president and CEO of Disaster Recovery Institute International, explains that while the agreement is a step forward in some ways, the world still has much more to work on in order to keep warming to below 2 degrees Celsius.
Jill and Carlo cover the latest with the infrastructure bill, the growing state rebellion over boosters, Trump's dereliction of duty on the pandemic, Taylor Swift's reign of cultural domination and more.
Aurora Cannabis CEO Miguel Martin joins Cheddar News' Closing Bell to discuss the company's latest earnings results, how it will achieve positive EBITDA by 2023, and the state of the cannabis industry amid potential U.S. federal legalization.
Moderna is defending its COVID-19 vaccine after a study found an increase in reports of myocarditis, which is an inflammation of the heart, in males ages 12 to 29 — about 13.3 cases in every 100,000 subjects. The pharmaceutical giant said the benefits of the vaccine outweigh the risk of the possible negative side effect.
The parent company of North Face, Vans and Supreme, VF Corp, released its fourth annual "Made for Change" sustainability and responsibility report. It details the company's ongoing efforts to tackle social and climate related issues. This comes as climate experts continue to warn about the dangers of fast fashion and its impact on global CO2 emissions. Sean Cady, Vice President of Global Sustainability, Responsibility and Trade at VF Corporation, joins Cheddar News to discuss.
A jam-packed Freitag pod with Carlo and Baker: new Covid hotspots, Kyle Rittenhouse trial, Belarus making trouble for Europe, red-hot housing market, and how to manage a PR crisis the right way.
As the UN climate conference is set to wrap this week, we take a look at pledges that world leaders have signed onto so far and the most important developments to come out of COP26. Sandeep Pai, Senior Research Lead at the Just Transition Initiative, joins Cheddar Climate to discuss the most important global initiatives and biggest pledges made by global leaders, and whether or not they can truly make an impact if two of the world's biggest economies, China and Russia, did not attend and are not fully committed to major climate initiatives.
A group of health experts from around the world is issuing a dire warning about the climate crisis, saying that climate change is the greatest global health threat facing the world this century and is set to become the 'defining narrative of human health.' The Lancet medical journal stated that warning in its annual report, along with a policy brief for the United States detailing actions the country can take to stop millions of unnecessary deaths. Director of Climate for Health at EcoAmerica Rebecca Rehr joined Cheddar Climate to discuss.
The COP26 summit in Scotland is in its final days, and the U.N. has just released a draft of an agreement for more than 200 world leaders to sign on Friday. The draft urges nations to set more aggressive goals in cutting emissions, while also calling for coal to be phased out. Chloe Demrovsky, President and CEO of Disaster Recovery Institute International, joins Cheddar News to discuss this agreement.
SpaceX and NASA have collaborated on another successful launch sending four astronauts to the international space station. The international crew will stay in orbit aboard the ISS for six months.
